Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Mar 19, 2018 10:29pm

187 Views

Post# 27743959

RE:RE:RE:To have so much riding on one news release

rtftech16 wrote: Ya a small amount. Thought it was better than the roulette table, just for fun. I can’t imagine having more than a couple percent of this in my portfolio. To those who have 10, 20, 30, 40+ percent holy moly that’s one strategy to guarantee capital loss over the long term, no matter how many times you get lucky in the short term

lol just checked my account. ATE is at 9.99% (for real) of my portfolio, but only because its risen so much is the past few months. Why assume everybody has everything riding on this?

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December